Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

Understanding Your Path: An Orientation to Early-Onset ADAD

At a Glance

Early-Onset Autosomal Dominant Alzheimer Disease (ADAD) is a rare, inherited condition caused by mutations in the PSEN1, PSEN2, or APP genes, with symptoms often starting in a person's 30s to 50s. Today, at-risk individuals have proactive options, including preventive clinical trials and advanced family planning to protect future generations.

Receiving a diagnosis or learning about a high risk for Early-Onset Autosomal Dominant Alzheimer Disease (ADAD) can feel like the ground has shifted beneath you. It is natural to feel a sense of panic, but it is important to remember that you are entering a space of intense scientific focus and supportive community. Unlike the more common forms of Alzheimer’s, ADAD is a rare, specific condition where the cause is a single, identifiable genetic change [1][2].

Understanding the facts can help move you from a state of emergency to a state of informed action.

Immediate Orientation: Three Stabilizing Facts

When first facing ADAD, these three points can help ground your perspective:

  1. You are not alone in the “unknown.” While ADAD is rare—accounting for less than 1% of all Alzheimer’s cases—there is a massive, global network of researchers and families dedicated specifically to this condition [1][3]. Programs like the Dominantly Inherited Alzheimer Network (DIAN) connect families across the world [4].
  2. The timeline is often predictable. In ADAD, the age when symptoms begin tends to be very consistent within a family [1]. This predictability, while difficult, provides a unique “window of opportunity” to plan your life, your career, and your medical care years before symptoms are expected to appear [5][6].
  3. Knowledge is a tool, not a destiny. Having the mutation does not mean there is nothing you can do. Today, mutation carriers have access to clinical trials aimed at preventing symptoms before they start—opportunities that were not available to previous generations [7][8].

How ADAD Differs from Common Alzheimer’s

It is a common misconception that ADAD is just “regular Alzheimer’s that starts early.” While they share the same biological markers, like amyloid and tau proteins in the brain, they are distinct in several ways [9][10]:

  • The Genetic Cause: Typical late-onset Alzheimer’s involves many risk genes and lifestyle factors. ADAD is monogenic, meaning it is caused by a mutation in one of three specific genes: PSEN1, PSEN2, or APP [2][1]. If a parent has the mutation, each child has a 50% chance of inheriting it.
  • Age of Onset: Typical Alzheimer’s usually affects people over age 65. ADAD symptoms often begin in a person’s 30s, 40s, or 50s [11][12].
  • Unique Symptoms: In addition to memory loss, some people with ADAD may experience “non-memory” symptoms earlier than in the common form, such as changes in walking (gait), muscle stiffness (spasticity), or even seizures [13][14].

Taking Control Through Research and Planning

Because the genetic cause of ADAD is so clear, it has become the “front line” for Alzheimer’s research. This gives you and your family options that didn’t exist a decade ago.

  • Observational Studies: Helping doctors track how the disease changes the brain years before symptoms start [15].
  • Prevention Trials: Testing new drugs in people who have the mutation but do not yet have symptoms, with the goal of stopping the disease in its tracks [15][8].

Family Planning Options

For those concerned about passing the mutation to their children, modern medicine offers paths to ensure future generations are free of the disease. Preimplantation Genetic Testing (PGT-M) combined with In Vitro Fertilization (IVF) allows doctors to test embryos for the specific family mutation and only implant those that do not carry it [16][17]. This process can even be done “blindly” (exclusion testing for embryos), where the parent does not have to learn their own genetic status if they prefer not to know [18].

The Role of Genetic Counseling

Before making decisions about testing or family planning, it is essential to speak with a genetic counselor [19]. These specialists help you navigate the psychological, ethical, and practical impact of genetic information, ensuring you make choices that align with your personal values [20][21].

Common questions in this guide

What genes cause early-onset autosomal dominant Alzheimer disease?
ADAD is caused by a mutation in one of three specific genes: PSEN1, PSEN2, or APP. If a parent carries one of these mutations, each of their children has a 50 percent chance of inheriting it.
How is ADAD different from typical Alzheimer's disease?
While both conditions involve amyloid and tau proteins in the brain, ADAD is caused by a single genetic mutation and typically begins much earlier, often in a person's 30s, 40s, or 50s. ADAD can also present with unique early symptoms like changes in walking or muscle stiffness.
Can I prevent passing the ADAD gene mutation to my children?
Yes, modern family planning offers options like Preimplantation Genetic Testing (PGT-M) combined with IVF. This allows doctors to test embryos for the family's specific gene mutation and only implant those that do not carry the disease-causing gene.
What is predictive testing for ADAD?
Predictive testing involves undergoing genetic testing to find out if you carry the ADAD mutation before you have any symptoms. Because this is a complex emotional and medical decision, it is highly recommended to work closely with a genetic counselor before getting tested.
Are there clinical trials available for people at risk for ADAD?
Yes, there are prevention trials and observational studies specifically for individuals who carry an ADAD mutation but do not yet show symptoms. Networks like the Dominantly Inherited Alzheimer Network (DIAN) help connect families to these critical research opportunities aimed at stopping or delaying the disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific gene mutation (PSEN1, PSEN2, or APP) has been identified in my family, and how does it typically affect the age of onset?
  2. 2.Can you refer me to a genetic counselor who has experience with 'pre-test' counseling and adult-onset neurodegenerative diseases?
  3. 3.How can I get involved with the Dominantly Inherited Alzheimer Network (DIAN) or the Alzheimer's Prevention Initiative (API)?
  4. 4.What are the pros and cons of 'predictive testing' (finding out my status before symptoms) versus waiting?
  5. 5.Are there any ongoing clinical trials for which I or my family members might be eligible, even if we are currently asymptomatic?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).

    McKay NS, Gordon BA, Hornbeck RC, et al.

    Nature neuroscience 2023; (26(8)):1449-1460 doi:10.1038/s41593-023-01359-8.

    PMID: 37429916
  2. 2

    Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2.

    Marsh JA, Huang G, Bowling K, et al.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2025; (22(3)):e00527 doi:10.1016/j.neurot.2025.e00527.

    PMID: 39875235
  3. 3

    15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.

    Daniels AJ, McDade E, Llibre-Guerra JJ, et al.

    medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.08.08.24311689.

    PMID: 39148846
  4. 4

    15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN.

    Daniels AJ, McDade E, Llibre-Guerra JJ, et al.

    NPJ dementia 2026; (2(1)):13 doi:10.1038/s44400-025-00047-7.

    PMID: 41709913
  5. 5

    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.

    Fortea J, Zaman SH, Hartley S, et al.

    The Lancet. Neurology 2021; (20(11)):930-942 doi:10.1016/S1474-4422(21)00245-3.

    PMID: 34687637
  6. 6

    Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

    Fortea J, Vilaplana E, Carmona-Iragui M, et al.

    Lancet (London, England) 2020; (395(10242)):1988-1997 doi:10.1016/S0140-6736(20)30689-9.

    PMID: 32593336
  7. 7

    Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.

    Rios-Romenets S, Lopera F, Sink KM, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2020; (16(7)):1023-1030 doi:10.1002/alz.12109.

    PMID: 32418361
  8. 8

    Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease.

    Cash DM, Morgan KE, O'Connor A, et al.

    The journal of prevention of Alzheimer's disease 2025; (12(6)):100133 doi:10.1016/j.tjpad.2025.100133.

    PMID: 40118731
  9. 9

    The role of the Alzheimer's Disease Neuroimaging Initiative in establishing the Dominantly Inherited Alzheimer Network.

    Morris JC, Buckles VD

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; (20(8)):5789-5791 doi:10.1002/alz.14106.

    PMID: 38958563
  10. 10

    Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.

    Morris JC, Weiner M, Xiong C, et al.

    Brain : a journal of neurology 2022; (145(10)):3594-3607 doi:10.1093/brain/awac181.

    PMID: 35580594
  11. 11

    Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease.

    Iaccarino L, Llibre-Guerra JJ, McDade E, et al.

    Brain communications 2024; (6(3)):fcae159 doi:10.1093/braincomms/fcae159.

    PMID: 38784820
  12. 12

    Genetics of dementia: insights from Latin America.

    Ramos C, Aguillon D, Cordano C, Lopera F

    Dementia & neuropsychologia 2020; (14(3)):223-236 doi:10.1590/1980-57642020dn14-030004.

    PMID: 32973976
  13. 13

    Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

    Vöglein J, Paumier K, Jucker M, et al.

    Brain : a journal of neurology 2019; (142(5)):1429-1440 doi:10.1093/brain/awz050.

    PMID: 30897203
  14. 14

    Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer's disease.

    Levitis E, Vogel JW, Funck T, et al.

    Brain communications 2022; (4(3)):fcac085 doi:10.1093/braincomms/fcac085.

    PMID: 35602652
  15. 15

    Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease.

    Keret O, Staffaroni AM, Ringman JM, et al.

    Alzheimer's & dementia (Amsterdam, Netherlands) 2021; (13(1)):e12197 doi:10.1002/dad2.12197.

    PMID: 34258377
  16. 16

    An attractive alternative to prenatal diagnosis: a case report of preimplantation genetic testing in familial cardiomyopathy.

    Pandey S, Khandhedia P

    AJOG global reports 2025; (5(2)):100476 doi:10.1016/j.xagr.2025.100476.

    PMID: 40231191
  17. 17

    Genetic counseling for pre-implantation genetic testing of monogenic disorders (PGT-M).

    Parikh F, Athalye A, Madon P, et al.

    Frontiers in reproductive health 2023; (5()):1213546 doi:10.3389/frph.2023.1213546.

    PMID: 38162012
  18. 18

    Protocol considerations for multigenerational blinding of preimplantation genetic testing for a monogenic condition for Huntington disease: a case report.

    Raine S, Siegel DR, Rabkina L, et al.

    F&S reports 2025; (6(2)):201-205 doi:10.1016/j.xfre.2025.03.007.

    PMID: 40620380
  19. 19

    Use of preimplantation genetic testing for monogenic adult-onset conditions: an Ethics Committee opinion.

    Fertility and sterility 2024; (122(4)):607-611 doi:10.1016/j.fertnstert.2024.05.165.

    PMID: 38944787
  20. 20

    Subjects at Risk for Genetic Late-Onset Neurological Diseases: Objective Knowledge.

    Leite Â, Leite F, Dinis MAP

    Public health genomics 2017; (20(3)):158-165 doi:10.1159/000479292.

    PMID: 28813711
  21. 21

    Elaboration of the Reciprocal-Engagement Model of Genetic Counseling Practice: a Qualitative Investigation of Goals and Strategies.

    Redlinger-Grosse K, Veach PM, LeRoy BS, Zierhut H

    Journal of genetic counseling 2017; (26(6)):1372-1387 doi:10.1007/s10897-017-0114-7.

    PMID: 28643080

This page provides educational information about Early-Onset Autosomal Dominant Alzheimer Disease (ADAD) and genetic testing. It is not a substitute for professional medical advice, diagnosis, or formal genetic counseling.

Get notified when new evidence is published on Early-onset autosomal dominant Alzheimer disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.